SOLARA ACTIVE PHARMA SCIENCES LIMITED

BSE: SOLARA541540ISIN INE624Z01016

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹645.40+16.15 (+2.57%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹774.00
52W low: ₹422.85
Off 52W high: -16.61%
1M return: -4.60%
3M return: +25.49%
6M return: +25.74%
1Y return: +4.54%
20D avg volume: 20,374
50 DMA: ₹673.30
200 DMA: ₹556.33

Key ratios Consolidated

Market cap: ₹3,102 Cr
Current price: ₹645.40
52W high / low: ₹774.00 / ₹422.85
Face value: ₹10.00
P/E: 84.30
P/B: 2.16
EPS (TTM): ₹7.66
Book value / share: ₹298.19
ROE: —
ROCE: 6.10%
Operating margin: —
Net margin: —
Debt / equity: 0.53
Net debt: ₹660.06 Cr
Interest cover: 0.92
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 128.8 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	417.34	381.60	387.29	349.00	313.54	319.15	273.01	300.31	346.95	363.49	299.43	248.73
	0.54	2.69	4.69	0.00	0.49	0.98	5.95	1.49	0.32	0.56	1.70	0.45
	417.88	384.29	391.98	349.00	314.03	320.13	278.96	301.80	347.27	364.05	301.13	249.18
	384.92	367.98	383.24	359.68	324.13	309.61	281.06	293.71	339.26	377.51	345.61	461.75
	217.80	180.81	182.23	175.71	149.69	165.14	143.67	143.96	156.93	137.10	158.38	157.76
	2.30	0.86	0.77	2.72	0.00	0.00	5.05	—	0.70	—	0.15	0.25
	57.62	56.05	55.47	55.23	54.86	53.64	52.29	51.67	52.71	55.02	56.01	62.64
	17.78	21.64	27.57	22.45	20.83	23.90	29.12	26.54	28.28	30.87	30.69	25.37
	26.64	26.71	26.04	25.57	24.49	23.58	24.30	24.54	25.34	25.07	25.25	25.96
	69.21	67.15	76.72	69.83	69.95	62.02	57.26	56.10	61.04	—	73.68	132.26
	32.96	16.31	8.74	-10.68	-10.10	10.52	-2.10	8.09	8.01	-13.46	-44.48	-212.57
	-4.50	0.00	0.86	-6.75	0.00	0.00	0.00	0.00	0.00	0.00	-122.18	-62.77
	28.46	16.31	9.60	-17.43	-10.10	10.52	-2.10	8.09	8.01	-13.46	-166.66	-275.34
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	88.79	0.00
	28.46	16.31	9.60	-17.43	-10.10	10.52	-2.10	8.09	8.01	-13.46	-255.45	-275.34
	5.92	3.52	2.20	-3.98	-2.36	2.46	-0.93	2.03	2.54	-3.50	-70.93	-76.49
Key metrics
	72.88	64.66	63.21	30.59	35.22	58.00	51.32	59.17	61.63	42.48	-110.72	-224.01
	17.50%	16.90%	16.30%	8.80%	11.20%	18.20%	18.80%	19.70%	17.80%	11.70%	-37.00%	-90.10%
	6.80%	4.30%	2.50%	-5.00%	-3.20%	3.30%	-0.80%	2.70%	2.30%	-3.70%	-85.30%	-110.70%
	2.70%	—	2.60%	—	0.80%	—	2.10%	—	—	—	—	—
	33.10%	19.60%	41.90%	16.20%	-9.60%	-12.20%	-8.80%	20.70%	—	—	—	—
	381.80%	55.00%	557.10%	-315.50%	-226.10%	178.20%	99.20%	102.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,535	1,369	1,284	1,289	1,444	1,268
	7.92	6.16	8.32	5.37	22.55	20.02
	1,543	1,375	1,292	1,294	1,466	1,288
	1,496	1,377	1,292	1,593	1,511	1,376
	756.55	672.77	581.66	760.65	773.89	858.86
	6.65	3.49	5.75	5.10	7.88	53.78
	224.37	219.20	211.69	243.92	228.63	236.34
	89.44	94.75	114.81	105.11	90.06	75.28
	104.96	99.68	99.25	103.33	111.19	112.32
	282.91	278.52	239.38	335.16	292.47	298.14
	47.33	-1.52	0.54	-298.25	-44.81	-87.61
	-10.39	-5.89	0.00	-190.17	0.00	-3.49
	36.94	-7.41	0.54	-488.42	-44.81	-91.10
	0.00	0.00	0.00	78.54	22.57	32.81
	36.94	-7.41	0.54	-566.96	-22.24	-58.29
	7.66	-1.68	0.14	-157.62	-6.16	-16.18
Key metrics
	231.34	187.02	214.60	-279.98	156.44	96.50
	15.07%	13.70%	16.70%	-21.70%	10.80%	7.60%
	2.41%	-0.50%	0.00%	-44.00%	-1.50%	-4.60%
	—	6.10%	9.00%	—	—	—
	27.30%	6.60%	-0.40%	-10.70%	13.80%	—
	476.29%	-1,472.20%	100.10%	-2,449.30%	61.80%	—
	—	100.09	172.88	—	—	—
	—	-20.64	394.11	—	—	—
	—	0.53	0.71	—	—	—
	—	660.06	772.11	—	—	—
	—	128.8	112.6	—	—	—
Balance sheet
	—	2,333	2,232	—	—	—
	—	858.10	728.73	—	—	—
	—	4.48	3.95	—	—	—
	—	438.72	326.57	—	—	—
	—	317.87	317.90	—	—	—
	—	41.60	67.77	—	—	—
	—	793.18	738.68	—	—	—
	—	273.90	248.62	—	—	—
	—	893.91	944.11	—	—	—
	—	664.54	776.06	—	—	—
	—	554.09	662.20	—	—	—
	—	110.45	113.86	—	—	—
	—	1,256	1,097	—	—	—
Cash flow
	—	152.91	212.82	—	—	—
	—	-98.83	-36.83	—	—	—
	—	-53.55	-180.48	—	—	—
	—	52.82	39.94	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	417.34	381.60	387.29	349.00	313.54	319.15	273.01	300.31	346.95	363.49	299.43	248.73
	0.23	1.92	4.42	0.00	0.49	0.98	5.95	1.49	0.32	1.38	1.63	0.44
	417.57	383.52	391.71	349.00	314.03	320.13	278.96	301.80	347.27	364.87	301.06	249.17
	383.46	366.53	382.84	359.67	324.11	309.60	283.84	293.70	339.25	377.19	345.36	461.73
	217.80	180.81	182.23	175.71	149.69	165.14	143.67	143.96	156.93	137.10	158.39	157.76
	2.30	0.86	0.77	2.72	0.00	0.00	5.05	—	0.70	—	0.15	0.25
	57.62	56.05	55.47	55.23	54.86	53.64	52.28	51.67	52.71	55.02	56.01	62.64
	16.36	20.23	27.06	22.45	20.83	23.90	29.12	26.54	28.28	30.87	30.62	25.37
	26.64	26.71	26.04	25.57	24.49	23.58	24.30	24.54	25.34	25.07	25.10	25.96
	69.17	67.11	76.83	69.82	69.93	62.01	60.05	56.09	61.03	64.66	73.64	132.24
	34.11	16.99	8.87	-10.67	-10.08	10.53	-4.88	8.10	8.02	-12.32	-44.30	-212.56
	-4.50	0.00	0.86	-6.75	0.00	0.00	0.00	—	—	—	-123.32	-62.77
	29.61	16.99	9.73	-17.42	-10.08	10.53	-4.88	8.10	8.02	-12.32	-167.62	-275.33
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	88.79	—
	29.61	16.99	9.73	-17.42	-10.08	10.53	-4.88	8.10	8.02	-12.32	-256.41	-275.33
	6.16	3.67	2.23	-3.97	-2.36	2.46	-1.65	2.47	2.11	-3.20	-71.23	-76.49
Key metrics
	72.61	63.93	62.83	30.60	35.24	58.01	48.54	59.18	61.64	43.62	-111.90	-224.00
	17.40%	16.80%	16.20%	8.80%	11.20%	18.20%	17.80%	19.70%	17.80%	12.00%	-37.40%	-90.10%
	7.10%	4.50%	2.50%	-5.00%	-3.20%	3.30%	-1.80%	2.70%	2.30%	-3.40%	-85.60%	-110.70%
	2.80%	—	2.60%	—	0.80%	—	1.90%	—	—	—	—	—
	33.10%	19.60%	41.90%	16.20%	-9.60%	-12.20%	-8.80%	20.70%	—	—	—	—
	393.70%	61.30%	299.40%	-315.10%	-225.70%	185.50%	98.10%	102.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,535	1,369	1,284	1,289	1,444	1,268
	6.57	5.89	9.14	5.37	22.14	18.76
	1,542	1,375	1,293	1,294	1,466	1,287
	1,492	1,376	1,294	1,593	1,511	1,375
	756.55	672.77	581.66	760.66	773.90	858.86
	6.65	3.49	5.75	5.10	7.88	53.78
	224.37	219.20	211.68	243.92	228.05	234.20
	86.10	94.24	114.81	105.97	90.06	75.27
	104.96	99.68	99.25	103.03	110.90	112.01
	282.93	278.59	241.83	335.04	292.89	299.90
	49.30	-1.35	-1.08	-298.70	-44.78	-88.17
	-10.39	-5.89	0.00	-189.64	—	-3.49
	38.91	-7.24	-1.08	-488.34	-44.78	-91.66
	0.00	0.00	0.00	78.54	22.57	33.10
	38.91	-7.24	-1.08	-566.88	-22.21	-58.56
	8.09	-1.64	-0.27	-157.48	-6.17	-16.29
Key metrics
	229.97	186.68	212.98	-279.34	156.18	95.62
	14.98%	13.60%	16.60%	-21.70%	10.80%	7.50%
	2.53%	-0.50%	-0.10%	-44.00%	-1.50%	-4.60%
	—	6.30%	8.80%	—	—	—
	27.30%	6.60%	-0.40%	-10.70%	13.80%	—
	960.22%	-570.40%	99.80%	-2,452.40%	62.10%	—
	—	100.07	172.86	—	—	—
	—	-21.12	-197.04	—	—	—
	—	0.49	0.71	—	—	—
	—	611.03	772.25	—	—	—
	—	130.5	114.3	—	—	—
Balance sheet
	—	2,277	2,225	—	—	—
	—	808.69	728.60	—	—	—
	—	4.00	3.81	—	—	—
	—	438.87	326.57	—	—	—
	—	317.87	317.90	—	—	—
	—	41.51	67.78	—	—	—
	—	786.58	732.08	—	—	—
	—	267.58	242.59	—	—	—
	—	887.53	938.07	—	—	—
	—	615.03	776.06	—	—	—
	—	554.09	662.20	—	—	—
	—	60.94	113.86	—	—	—
	—	1,255	1,096	—	—	—
Cash flow
	—	152.89	212.80	—	—	—
	—	-50.14	-36.83	—	—	—
	—	-102.56	-180.48	—	—	—
	—	52.82	39.94	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -1.76%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +27.30%
Profit YoY (TTM): +960.22%

Consolidated

Sales CAGR 3Y: -1.76%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +27.30%
Profit YoY (TTM): +476.29%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 41.92%

Quarter	September 2026	June 2026
Promoter %	41.92%	41.92%

Holder	Type	Holding	Previous	Change
DEVICAM CAPITAL LLP	Promoter Group	15.47%	15.47%	0.00%
PRONOMZ VENTURES LLP	Promoter	9.71%	9.71%	0.00%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	3.78%	3.78%	0.00%
SPIRACCA VENTURES LLP.	Public	3.54%	3.54%	0.00%
SRJR ENTERPRISE LLP	Promoter Group	3.52%	3.52%	0.00%
ARUN KUMAR PILLAI	Promoter	3.46%	3.46%	0.00%
K R RAVISHANKAR	Promoter	2.75%	2.75%	0.00%
HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD	Public	2.17%	2.17%	0.00%
CHAYADEEP VENTURES LLP	Promoter Group	2.10%	2.10%	0.00%
AGNUS CAPITAL LLP	Promoter Group	1.76%	1.76%	0.00%
MAURYAN INDIA FUND	Public	1.62%	1.35%	+0.27%
THE SCOTTISH ORIENTAL SMALLER COMPANIES TRUSTPLC	Public	1.44%	2.33%	-0.89%
ROUTE ONE OFFSHORE MASTER FUND, L.P.	Public	1.44%	1.44%	0.00%
RAPTAKOS, BRETT AND CO. LTD.	Public	1.33%	1.38%	-0.05%
FSSA INDIAN SUBCONTINENT FUND AS SUB FUND OF FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC	Public	1.18%	1.83%	-0.65%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
SOLARA ACTIVE PHARMA SCIENCES LIMITED	3,102	645.40	84.30	6.10%	+27.30% TTM	+476.29% TTM	+4.54%

Filings & corporate actions

Recent announcements

Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 202623 Oct 2026 · Company Update / Earnings Call Transcript
Solara Active Pharma Sciences Limited has informed the Exchange regarding the copy of Newspaper publication informing about Final Reminder-cum-Forfeiture Notice for the payment of First ....19 Oct 2026 · Company Update / Newspaper Publication
Solara Active Pharma Sciences Limited has informed the Exchange regarding the dispatch of Final Reminder -cum-Forfeiture Notice for the payment of outstanding call money to the holders ....17 Oct 2026 · Company Update / General
Solara Active Pharma Sciences Limited has informed the Exchange regarding the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....17 Oct 2026 · Company Update / Newspaper Publication
Monitoring Agency Report for the quarter ended September 30, 202616 Oct 2026 · Company Update / Monitoring Agency Report
Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 202616 Oct 2026 · Company Update / Analyst / Investor Meet
Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 202616 Oct 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 202416 Oct 2026 · Company Update / General
Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara''s Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA ....16 Oct 2026 · Company Update / Press Release / Media Release
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options.16 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....16 Oct 2026 · Result / Financial Results
Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....16 Oct 2026 · Board Meeting / Outcome of Board Meeting
Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, October 16, 2026, at 4.00 PM IST to discuss the Company''s ....13 Oct 2026 · Company Update / Analyst / Investor Meet
Solara Active Pharma has informed the Exchange regarding the ESG Rating received from Crisil ESG Rating & Analytics Limited10 Oct 2026 · Company Update / General
Update on approval of Final Reminder cum Forfeiture Notice for payment of outstanding call money.9 Oct 2026 · Company Update / General
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/10/2026 ,inter alia, to consider and approve unaudited financial ....9 Oct 2026 · Board Meeting / Board Meeting
Solara Active Pharma Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended ....9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation to furnish valid PAN. KYC details and Nomination by shareholders holding physical Shares26 Sep 2026 · Company Update / General
Intimation regarding Closure of Trading window for the quarter ended September 30, 202625 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer''s report of the Ninth Annual General Meeting22 Sep 2026 · AGM/EGM / AGM
Solara Active Pharma Sciences Limited has informed the Exchange regarding the Proceedings of Ninth Annual General Meeting held on September 18, 2026.18 Sep 2026 · AGM/EGM / AGM
Solara Active Pharma Sciences Limited has informed the exchange about intimation in connection with the receipt of Rectification Order28 Aug 2026 · Company Update / General
Newspaper publication regarding the completion of dispatch of 9th AGM Notice and Annual report26 Aug 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Reporting for the financial year 2025-26.25 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the financial year ended March 31, 202625 Aug 2026 · Others / Reg. 34 (1) Annual Report
Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) of the Company scheduled to be held on Friday, September 18, 202625 Aug 2026 · AGM/EGM / AGM
Solara Active Pharma Sciences Limited has informed the stock exchange regarding the Newspaper publication with respect to the Ninth Annual General Meeting.24 Aug 2026 · Company Update / Newspaper Publication
Conversion of Partly paid-up Rights Equity Shares into fully paid-up Equity shares in relation to the rights issue by the Company, upon receipt of Call Monies, as applicable.19 Aug 2026 · Company Update / General
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options18 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Solara Active Pharma Sciences Limited has informed the exchange regarding the update with respect to our intimation dated July 23, 2026, regarding appointment of Chief Information Officer ....7 Aug 2026 · Company Update / General
Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended June 30, 202629 Jul 2026 · Company Update / Earnings Call Transcript
Solara Active Pharma Sciences Limited has informed the exchange about the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....24 Jul 2026 · Company Update / Newspaper Publication
Solara Active Pharma Sciences Limited has informed the exchange regarding submission of Machine Readable copy of Financial results for the quarter ended June 30, 202624 Jul 2026 · Company Update / General
Solara Active Pharma Sciences Limited has informed the exchange about the Audio Recording of the Q1 FY 27 Earnings call held on July 23, 2026, at 16.00 IST23 Jul 2026 · Company Update / Analyst / Investor Meet
Monitoring Agency Report for the quarter ended June 30, 202623 Jul 2026 · Company Update / Monitoring Agency Report
Solara Active Pharma Sciences Limited has informed the exchange that there is no Deviation and Variation of funds raised through Rights Issue for the quarter ended June 30, 202623 Jul 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 Equity Shares pursuant to exercise of ESOP options.23 Jul 2026 · Company Update / Allotment of ESOP / ESPS
Solara Active Pharma Sciences Limited has informed the exchange regarding the appointment of Mr. Ajit Manocha as Chief Information Officer (CIO) and designated him as Senior Management ....23 Jul 2026 · Company Update / General
Solara Active Pharma Sciences Limited has informed the exchange regarding the Press Release dated July 23, 2026, titled- Solara reports strong Q1''27 Base business performance with continued ....23 Jul 2026 · Company Update / Press Release / Media Release
Solara Active Pharma Sciences Limited has informed the exchange regarding the Press Release dated July 23, 2026, titled - Solara reports Strong Q1''27 Base business performance with Continued ....23 Jul 2026 · Company Update / Press Release / Media Release

Board meetings

16 Oct 2026 Board Meeting - Financial Results
23 Jul 2026 Board Meeting - Financial Results